Webinar Date/Time: Thursday, May 23, 2024 at 10am EDT | 7am PDT | 3pm BST | 4pm CEST
Gain insight from this webinar series on leveraging technology to optimize clinical trial protocols and outcomes that comply with stringent regulatory requirements.
Register Free: https://www.pharmexec.com/pe/data-ecosystem
Event Overview:
Significant advances in technology are providing new opportunities to collect and utilize real-world data to establish better clinical trial protocols that have a patient-centric focus and the ability to transform healthcare. However, it is important to understand how such applications work and their impact on safety.
This webcast series uncovers the concerns of safety professionals and other stakeholders involved in the development and implementation of clinical trial protocols in the digital era and highlights methods to best apply digital data into routine practice to best optimize trial success and adhere to strict regulatory guidance.
Key Learning Objectives
Who Should Attend
Full Agenda
Thursday, May 23rd:
10:00 am EDT Oracle and Cerner: A Leap Forward in Safety
Michael Fronstin, Global Head of Clinical Research and Consulting; Oracle Cerner Enviza
Bruce Palsulich, Vice President of Product Strategy; Oracle Health Sciences
11:00 am EDT Automating Study Setup with a Digital Data Flow
Julie Smiley, Sr. Director, Life Sciences Product Strategy; Oracle, and other non-Oracle speakers.
12:00 pm EDT Building a Thriving Culture of Innovation in Pharmacovigilance
Non-Oracle speakers
Speakers:
Michael Fronstin
Global Head of Clinical Research and Consulting
Oracle Cerner Enviza
Bruce Palsulich
Vice President of Product Strategy
Oracle Health Sciences
Julie Smiley
Sr. Director, Life Sciences Product Strategy
Oracle
Register Free: https://www.pharmexec.com/pe/data-ecosystem
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Bristol Myers Squibb’s Cobenfy Falls Short in Phase III Trial as Add On Therapy for Schizophrenia
April 23rd 2025In the Phase III ARISE trial, Cobenfy administered as an adjunctive treatment to atypical antipsychotics for patients with inadequately controlled schizophrenia did not achieve statistically significant improvements.